Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "C-mo"

180 News Found

Biocytogen and Sihuan Pharmaceutical forge strategic pact to accelerate antibody-based therapies
R&D | April 03, 2026

Biocytogen and Sihuan Pharmaceutical forge strategic pact to accelerate antibody-based therapies

The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development


Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
Drug Approval | March 18, 2026

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options


KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units
Hospitals | March 10, 2026

KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units

The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management


Novo Nordisk & Vivtex team up to revolutionize oral hiologics
News | February 27, 2026

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk


Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill
News | February 21, 2026

Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill

The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats


Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
News | February 19, 2026

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar


BioAsia 2026 positions Telangana as a global TechBio powerhouse
News | February 14, 2026

BioAsia 2026 positions Telangana as a global TechBio powerhouse

BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem